HilleVax

HilleVax was a biopharmaceutical company focused on the development and commercialisation of novel vaccine candidates. Its initial programme, HIL-214, was a virus-like particle (VLP)-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax listed on NASDAQ in April 2022 with the ticker: HLVX. Subsequent to the 2024 announcement of negative results from a Phase 2b clinical trial of HIL-214 in infants, Hillevax was acquired by Xoma Royalty (NASDAQ: XOMA) in 2025.